Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Novartis AGTrade
abrdn Physical Palladium Shares ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs abrdn Physical Palladium Shares ETF — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while abrdn Physical Palladium Shares ETF trades at $24.87. The key difference: Novartis AG pays a 3.02% dividend while abrdn Physical Palladium Shares ETF pays none, and Novartis AG is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.

NVSPALL
Market Cap
$298.18B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$168.62$37.18
52-Week Low
$119.31$19.96
Enterprise Value
$339.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

abrdn Physical Palladium Shares ETF

PALL trades at $25.05, up 0.64% with bullish technical signals from moving averages. The stock recently underwent a 1:5 split on May 18, 2026. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend strength. Support and resistance levels cluster around $25-$26, creating a key price zone.

PALL presents a contrarian opportunity as palladium prices remain 47% below January 2026 highs. Supply risks and industrial demand support long-term fundamentals, though the ETF faces commodity price volatility and Federal Reserve policy uncertainty as near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About abrdn Physical Palladium Shares ETF

PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.

Read more on PALL